Skip to content
10-Q

Quarterly Report

Impact BioMedical, INC. IBO

0001493152-24-044792

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 25, 2024 11.5M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $2.67M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $1K
Stockholders Equity Q3 2024 · Sep 30, 2024 $31.35M
Stockholders Equity Q3 2024 · Dec 31, 2023 $25.22M
Current Liabilities Q3 2024 · Sep 30, 2024 $1.14M
Current Liabilities Q3 2024 · Dec 31, 2023 $13.14M
Total Liabilities Q3 2024 · Sep 30, 2024 $12.34M
Total Liabilities Q3 2024 · Dec 31, 2023 $16.37M
Current Assets Q3 2024 · Sep 30, 2024 $3.18M
Current Assets Q3 2024 · Dec 31, 2023 $332K
Total Assets Q3 2024 · Sep 30, 2024 $46.7M
Total Assets Q3 2024 · Dec 31, 2023 $44.63M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$2.42M
Short Term Debt Q3 2024 · Sep 30, 2023 $11.9M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.02
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.04
Eps Basic Q3 2024 · Sep 30, 2023 −$0.02
Eps Basic Q3 2024 · Sep 30, 2023 −$0.04
Sga Expense Q3 2024 · Sep 30, 2023 $101K
Sga Expense Q3 2024 · Sep 30, 2023 $182K
Rd Expense restated Q3 2024 · Sep 30, 2023 $357K
Rd Expense restated Q3 2024 · Sep 30, 2023 $1.06M
Net Income Q3 2024 · Sep 30, 2023 −$3.15M
Operating Income Q3 2024 · Sep 30, 2023 −$1.08M
Operating Income Q3 2024 · Sep 30, 2023 −$2.89M